Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316433 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Swedish Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00316433 is a Phase 2 study that was terminated before completion, run by Swedish Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT00316433, a Phase 2 study, was terminated before completion, sponsored by Swedish Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.
Interventions
- DRUG Irinotecan (CPT-11)
- DRUG Oxaliplatin (Eloxatin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316433
The ClinicalTrials.gov registry entry for NCT00316433 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan (CPT-11) is the first listed.
NCT00316433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316433 about?
NCT00316433 is a clinical study titled "Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer". The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.
What is the current status of trial NCT00316433?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2005-02. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00316433?
The interventions under investigation include: Irinotecan (CPT-11) (DRUG), Oxaliplatin (Eloxatin) (DRUG).
Who is sponsoring clinical trial NCT00316433?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.